Tsubakio T, Kitani T, Nagai K, Kanamaru A, Horiuchi A, Hasegawa H, Masaoka T, Shibata H, Kawagoe H, Shinohara Y, Yoshioka K, Kitawaki T, Nasu T
Jpn J Antibiot. 1981 Nov;34(11):1451-6.
Seventy patients with severe infection accompanying hematologic disorders including leukemia and lymphoma were treated with ticarcillin in combination with aminoglycosides and/or cephem derivatives. Of the 58 patients in whom the efficacy could be evaluated, 17 (29%) responded markedly and 22 (38%) moderately, the effective rate being 67%. Side effects attributable to the treatment were noted: rash in 2, fever and rash in 1, vascular pain in 2 (5 and 7 years of age). Renal and hepatic functions were abnormal in 4 each. However, these abnormal findings were not attributed to ticarcillin. These results indicate that ticarcillin is an effective and safe antibiotic for the treatment of severe infection accompanying hematologic malignancy when used in combination with aminoglycosides and/or cephem derivatives.
70例伴有血液系统疾病（包括白血病和淋巴瘤）的严重感染患者接受了替卡西林联合氨基糖苷类药物和/或头孢菌素衍生物治疗。在58例可评估疗效的患者中，17例（29%）显著有效，22例（38%）中度有效，有效率为67%。观察到治疗相关的副作用：2例出现皮疹，1例出现发热和皮疹，2例（年龄分别为5岁和7岁）出现血管疼痛。4例患者肾功能异常，4例患者肝功能异常。然而，这些异常表现并非由替卡西林所致。这些结果表明，替卡西林与氨基糖苷类药物和/或头孢菌素衍生物联合使用时，是治疗伴有血液系统恶性肿瘤的严重感染的一种有效且安全的抗生素。
